Participants 130 175 5
levodopa in patients with Parkinson's disease
Participants 355 582 6
Entacapone (OR-611), a novel COMT inhibitor, which does not cross the blood brain barrier, was assessed in 12 patients with Parkinson's disease and motor fluctuations in a randomised, double-blind, cross-over, single dose study
